A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
Clinical trial NCT06668064 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06668064
- Sponsor
- EyePoint Pharmaceuticals, Inc.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-22
- Primary completion
- 2026-08-01
- Enrollment
- 400
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.